Time course change of COX2-PGI2/TXA2 following global cerebral ischemia reperfusion injury in rat hippocampus

Behavioral and Brain Functions

Volumn 10, Issue 1, 2014, Pages

  Yu, Lijuan ^a   Yang, Bin ^a   Wang, Jia ^a   Zhao, Lei ^a   Luo, Weinan ^a   Jiang, Qingsong ^a   Yang, Junqing ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

COX2; Global cerebral ischemia reperfusion; Neuroinflammation; PGI2; PGI2 TXA2; TXA2

Indexed keywords

CYCLOOXYGENASE 2; MESSENGER RNA; PROSTACYCLIN; THROMBOXANE A2; MALONALDEHYDE; PROSTACYCLIN DERIVATIVE; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN ISCHEMIA; BRAIN LEVEL; CONTROLLED STUDY; DISEASE COURSE; GENE EXPRESSION; HIPPOCAMPUS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION INJURY; SHAM PROCEDURE; TIME; ANIMAL; BRAIN CIRCULATION; ENZYMOLOGY; MAZE TEST; MEMORY; METABOLISM; PHYSIOLOGY; PSYCHOLOGY; WISTAR RAT;

ANIMALS; BRAIN ISCHEMIA; CEREBROVASCULAR CIRCULATION; CYCLOOXYGENASE 2; HIPPOCAMPUS; MALE; MALONDIALDEHYDE; MAZE LEARNING; MEMORY; PROSTAGLANDINS I; RATS; RATS, WISTAR; REPERFUSION INJURY; SUPEROXIDE DISMUTASE; THROMBOXANE A2;

EID: 84927173690     PISSN: None     EISSN: 17449081     Source Type: Journal    
DOI: 10.1186/1744-9081-10-42     Document Type: Article

References (59)

1. Paul SL, Srikanth VK, Thrift AG: The large and growing burden of stroke. Curr Drug Targets 2007, 8:786-793.
2. Ma M, Uekawa K, Hasegawa Y, Nakagawa T, Katayama T, Sueta D, Toyama K, Kataoka K, Koibuchi N, Kuratsu J, Kim-Mitsuyama S: Pretreatment with rosuvastatin protects against focal cerebral ischemia/reperfusion injury in rats through attenuation of oxidative stress and inflammation. Brain Res 2013, 1519:87-94.
3. Mehta SL, Manhas N, Raghubir R: Molecular targets in cerebral ischemia for developing novel therapeutics. Brain Res Rev 2007, 54:34-66.
4. Woodward DF, Jones RL, Narumiya S: International Union of Basic and Clinical Pharmacology. LXXXIII: classification of prostanoid receptors, updating 15 years of progress. Pharmacol Rev 2011, 63:471-538.
5. Hata AN, Breyer RM: Pharmacology and signaling of prostaglandin receptors: multiple roles in inflammation and immune modulation. Pharmacol Ther 2004, 103:147-166.
6. Yang H, Chen C: Cyclooxygenase-2 in synaptic signaling. Curr Pharm Des 2008, 14:1443-1451.
7. Minghetti L: Cyclooxygenase-2 (COX2) in inflammatory and degenerative brain diseases. J Neuropathol Exp Neurol 2004, 63:901-910.
8. Manev H, Chen H, Dzitoyeva S, Manev R: Cyclooxygenases and 5-lipoxygenase in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 2011, 35:315-319.
9. Gaur V, Kumar A: Effect of nonselective and selective COX2 inhibitors on memory dysfunction, glutathione system, and tumor necrosis factor alpha level against cerebral ischemia reperfusion injury. Drug Chem Toxicol 2012, 35:218-224.
10. Sasaki T, Kitagawa K, Yamagata K, Takemiya T, Tanaka S, Omura-Matsuoka E, Sugiura S, Matsumoto M, Hori M: Amelioration of hippocampal neuronal damage after transient forebrain ischemia in cyclooxygenase-2-deficient mice. J Cereb Blood Flow Metab 2004, 24:107-113.
11. Khan M, Fraser A: COX2 inhibitors and the risk of cardiovascular thrombotic events. Ir Med J 2012, 105:119-121.
12. Wei G, Kibler KK, Koehler RC, Maruyama T, Narumiya S, Doré S: Prostacyclin receptor deletion aggravates hippocampal neuronal loss after bilateral common carotid artery occlusion in mouse. Neuroscience 2008, 156:1111-1117.
13. Akram A, Gibson CL, Grubb BD: Neuroprotection mediated by the EP4 receptor avoids the detrimental side effects of COX2 inhibitors following ischaemic injury. Neuropharmacology 2013, 65:165-172.
14. Nishimaki S, Seki K: An imbalance between prostacyclin and thromboxane in relation to cerebral blood flow in neonates with maternal preeclampsia. Prostaglandins Other Lipid Mediat 1999, 58:43-49.
15. Karasawa Y, Komiyama H, Yoshida S, Hino N, Katsuura Y, Nakaike S, Araki H: Effect of TTC-909 on cerebral infarction following permanent occlusion of the middle cerebral artery in stroke prone spontaneously hypertensive rats. J Pharmacol Sci 2003, 91:305-312.
16. Ohyama H, Hosomi N, Takahashi T, Mizushige K, Kohno M: Thrombin inhibition attenuates neurodegeneration and cerebral edema formation following transient forebrain ischemia. Brain Res 2001, 902:264-271.
17. de Leval X, Hanson J, David JL, Masereel B, Pirotte B, Dogné JM: New developments on thromboxane and prostacyclin modulators part II: prostacyclin modulators. Curr Med Chem 2004, 11:1243-1252.
18. Dogné JM, de Leval X, Hanson J, Frederich M, Lambermont B, Ghuysen A, Casini A, Masereel B, Ruan KH, Pirotte B, Kolh P: New developments on thromboxane and prostacyclin modulators part I: thromboxane modulators. Curr Med Chem 2004, 11:1223-1241.
19. Shohami E, Globus M, Weidenfeld J: Regional distribution of prostanoids in rat brain: effect of insulin and 2-deoxyglucose. Exp Brain Res 1985, 61:87-90.
20. Fang YC, Wu JS, Chen JJ, Cheung WM, Tseng PH, Tam KB, Shyue SK, Chen JJ, Lin TN: Induction of prostacyclin/PGI2 synthase expression after cerebral ischemia-reperfusion. J Cereb Blood Flow Metab 2006, 26:491-501.
21. Takechi H, Matsumura K, Watanabe Y, Kato K, Noyori R, Suzuki M, Watanabe Y: A novel subtype of the prostacyclin receptor expressed in the central nervous system. J Biol Chem1996, 271:5901-5906.
22. Yagami T, Takahara Y, Ishibashi C, Sakaguchi G, Itoh N, Ueda K, Nakazato H, Okamura N, Hiramatsu Y, Honma T, Arimura A, Sakaeda T, Katsuura G: Amyloid beta protein impairs motor function via thromboxane A2 in the rat striatum. Neurobiol Dis 2004, 16:481-489.
23. Yokota C, Kaji T, Kuge Y, Inoue H, Tamaki N, Minematsu K: Temporal and topographic profiles of cyclooxygenase-2 expression during 24 h of focal brain ishemia in rats. Neurosci Lett 2004, 357:219-222.
24. Huttemeier PC, Kamiyama Y, Su M, Watkins WD, Benveniste H: Microdialysis measurements of PGD2, TXB2 and 6-KETO-PGF1 alpha in rat CA1 hippocampus during transient cerebral ischemia. Prostaglandins 1993, 45:177-187.
25. Cheng O, Li Z, Han Y, Jiang Q, Yan Y, Cheng K: Baicalin improved the spatial learning ability of global ischemia/reperfusion rats by reducing hippocampal apoptosis. Brain Res 2012, 1470:111-118.
26. Kuang G, He Q, Zhang Y, Zhuang R, Xiang A, Jiang Q, Luo Y, Yang J: Modulation of preactivation of PPAR-β on memory and learning dysfunction and inflammatory response in the hippocampus in rats exposed to global cerebral ischemia/reperfusion. PPAR Res 2012, 2012:209794.
27. Wang H, Jiang R, He Q, Zhang Y, Zhang Y, Li Y, Zhuang R, Luo Y, Li Y, Wan J, Tang Y, Yu H, Jiang Q, Yang J: Expression pattern of peroxisome proliferator-activated receptors in rat hippocampus following cerebral ischemia and reperfusion injury. PPAR Res 2012, 2012:596394.
28. Song Y, Liu J, Zhang F, Zhang J, Shi T, Zeng Z: Antioxidant effect of quercetin against acute spinal cord injury in rats and its correlation with the p38MAPK/iNOS signaling pathway. Life Sci 2013, 92:1215-1221.
29. Whittaker N, Bunting S, Salmon J, Moncada S, Vane JR, Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF: The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 1976, 12:915-928.
30. Brash AR, Jackson EK, Saggese CA, Lawson JA, Oates JA, FitzGerald GA: Metabolic disposition of prostacyclin in humans. J Pharmacol Exp Ther 1983, 226:78-87.
31. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA: Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986, 77:590-594.
32. Manzanero S, Santro T, Arumugam TV: Neuronal oxidative stress in acute ischemic stroke: sources and contribution to cell injury. Neurochem Int 2013, 62:712-718.
33. Ohsawa I, Ishikawa M, Takahashi K, Watanabe M, Nishimaki K, Yamagata K, Katsura K, Katayama Y, Asoh S, Ohta S: Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat Med 2007, 13:688-694.
34. Kumar A, Mittal R, Khanna HD, Basu S: Free radical injury and blood-brain barrier permeability in hypoxic-ischemic encephalopathy. Pediatrics 2008, 122:e722-e727.
35. Wu KJ, Hsieh MT, Wu CR, Wood WG, Chen YF: Green tea extract ameliorates learning and memory deficits in ischemic rats via its active component polyphenol epigallocatechin-3-gallate by modulation of oxidative stress and neuroinflammation. Evid Based Complement Alternat Med 2012, 2012:163106.
36. Cherubini A, Ruggiero C, Polidori MC, Mecocci P: Potential markers of oxidative stress in stroke. Free Radic Biol Med 2005, 39:841-852.
37. Candelario-Jalil E, Mhadu NH, Al-Dalain SM, Martínez G, León OS: Time course of oxidative damage in different brain regions following transient cerebral ischemia in gerbils. Neurosci Res 2001, 41:233-241.
38. Yang J, Liu B, He B, Zhou Q: Protective effects of meloxicam on aluminum overload-induced cerebral damage in mice. Eur J Pharmacol 2006, 547:2-8.
39. Borre Y, Lemstra S, Westphal KG, Morgan ME, Olivier B, Oosting RS: Celecoxib delays cognitive decline in an animal model of neurodegeneration. Behav Brain Res 2012, 234:285-291.
40. Zhao Y, Patzer A, Herdegen T, Gohlke P, Culman J: Activation of cerebral peroxisome proliferator-activated receptors gamma promotes neuroprotection by attenuation of neuronal cyclooxygenase-2 overexpression after focal cerebral ischemia in rats. FASEB J 2006, 20:1162-1175.
41. Im JY, Kim D, Paik SG, Han PL: Cyclooxygenase-2-dependent neuronal death proceeds via superoxide anion generation. Free Radic Biol Med 2006, 41:960-972.
42. Lee J, Kosaras B, Aleyasin H, Han JA, Park DS, Ratan RR, Kowall NW, Ferrante RJ, Lee SW, Ryu H: Role of cyclooxygenase-2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response. FASEB J 2006, 20:2375-2377.
43. Cannon CP, Cannon PJ: Physiology. COX2 inhibitors and cardiovascular risk. Science 2012, 336:1386-1387.
44. Hao CM, Redha R, Morrow J, Breyer MD: Peroxisome proliferator-activated receptor delta activation promotes cell survival following hypertonic stress. J Biol Chem 2002, 277:21341-21345.
45. Saleem S, Shah ZA, Maruyama T, Narumiya S, Doré S: Neuroprotective properties of prostaglandin I2 IP receptor in focal cerebral ischemia. Neuroscience 2010, 170:317-323.
46. Matsuo Y, Izumiyama M, Onodera H, Kurosawa A, Kogure K: Effect of a novel thromboxane A2 receptor antagonist, S-1452, on postischemic brain injury in rats. Stroke 1993, 24:2059-2064.
47. Zhu HB, Zhang L, Wang ZH, Tian JW, Fu FH, Liu K, Li CL: Therapeutic effects of hydroxysafflor yellow A on focal cerebral ischemic injury in rats and its primary mechanisms. J Asian Nat Prod Res 2005, 7:607-613.
48. Marmol F, Puig-Parellada P, Sanchez J, Trullas R: Influence of aging on thromboxane A2 and prostacyclin levels in rat hippocampal brain slices. Neurobiol Aging 1999, 20:695-697.
49. Lundblad C, Grände PO, Bentzer P: Increased cortical cell loss and prolonged hemodynamic depression after traumatic brain injury in mice lacking the IP receptor for prostacyclin. J Cereb Blood Flow Metab 2008, 28:367-376.
50. Xiao CY, Hara A, Yuhki K, Fujino T, Ma H, Okada Y, Takahata O, Yamada T, Murata T, Narumiya S, Ushikubi F: Roles of prostaglandin I(2) and thromboxane A(2) in cardiac ischemia-reperfusion injury: a study using mice lacking their respective receptors. Circulation 2001, 104:2210-2215.
51. Cui Y, Kataoka Y, Satoh T, Yamagata A, Shirakawa N, Watanabe Y, Suzuki M, Yanase H, Kataoka K, Watanabe Y: Protective effect of prostaglandin I(2) analogs on ischemic delayed neuronal damage in gerbils. Biochem Biophys Res Commun 1999, 265:301-304.
52. Cui Y, Takamatsu H, Kakiuchi T, Ohba H, Kataoka Y, Yokoyama C, Onoe H, Watanabe Y, Hosoya T, Suzuki M, Noyori R, Tsukada H, Watanabe Y: Neuroprotection by a central nervous system-type prostacyclin receptor ligand demonstrated in monkeys subjected to middle cerebral artery occlusion and reperfusion: a positron emission tomography study. Stroke 2006, 37:2830-2836.
53. Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T: Prostacyclindependent apoptosis mediated by PPAR delta. J Biol Chem 2001, 276:46260-46267.
54. Fauti T, Müller-Brüsselbach S, Kreutzer M, Rieck M, Meissner W, Rapp U, Schweer H, Kömhoff M, Müller R: Induction of PPARbeta and prostacyclin (PGI2) synthesis by Raf signaling: failure of PGI2 to activate PPAR beta. FEBS J 2006, 273:170-179.
55. Gao H, Peng B, Welch WJ, Wilcox CS: Central thromboxane receptors: mRNA expression and mediation of pressor responses. Am J Physiol 1997, 272:R1493-R1500.
56. Honma S, Saika M, Ohkubo S, Kurose H, Nakahata N: Thromboxane A2 receptor-mediated G12/13-dependent glial morphological change. Eur J Pharmacol 2006, 545:100-108.
57. Wacker MJ, Tevis O, Hanke J, Howard T, Gilbert W, Orr JA: Characterization of thromboxane A2 receptor and TRPV1 mRNA expression in cultured sensory neurons. Neurosci Lett 2012, 515:12-17.
58. Wacker MJ, Tyburski JB, Ammar CP, Adams MC, Orr JA: Detection of thromboxane A(2) receptor mRNA in rabbit nodose ganglion neurons. Neurosci Lett 2005, 386:121-126.
59. Lin H, Li HF, Lian WS, Chen HH, Lan YF, Lai PF, Cheng CF: Thromboxane A2 mediates iron-overload cardiomyopathy in mice through calcineurin-nuclear factor of activated T cells signaling pathway. Circ J 2013, 77:2586-2595.